CA2998134A1 - Compounds and formulations for treating ophthalmic diseases - Google Patents

Compounds and formulations for treating ophthalmic diseases Download PDF

Info

Publication number
CA2998134A1
CA2998134A1 CA2998134A CA2998134A CA2998134A1 CA 2998134 A1 CA2998134 A1 CA 2998134A1 CA 2998134 A CA2998134 A CA 2998134A CA 2998134 A CA2998134 A CA 2998134A CA 2998134 A1 CA2998134 A1 CA 2998134A1
Authority
CA
Canada
Prior art keywords
formulation
optionally substituted
pharmaceutical formulation
compound
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2998134A
Other languages
English (en)
French (fr)
Inventor
Jerry CAGLE
Angel Padilla
David Baker
Gary Cook
Harun Takruri
Leah MAKLEY
Emmett Cunningham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viewpoint Therapeutics Inc
Original Assignee
Viewpoint Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viewpoint Therapeutics Inc filed Critical Viewpoint Therapeutics Inc
Publication of CA2998134A1 publication Critical patent/CA2998134A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2998134A 2015-09-08 2016-09-08 Compounds and formulations for treating ophthalmic diseases Abandoned CA2998134A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562215629P 2015-09-08 2015-09-08
US62/215,629 2015-09-08
US201562269013P 2015-12-17 2015-12-17
US201562269019P 2015-12-17 2015-12-17
US62/269,013 2015-12-17
US62/269,019 2015-12-17
PCT/US2016/050823 WO2017044659A1 (en) 2015-09-08 2016-09-08 Compounds and formulations for treating ophthalmic diseases

Publications (1)

Publication Number Publication Date
CA2998134A1 true CA2998134A1 (en) 2017-03-16

Family

ID=58240060

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2998134A Abandoned CA2998134A1 (en) 2015-09-08 2016-09-08 Compounds and formulations for treating ophthalmic diseases

Country Status (8)

Country Link
US (1) US20180250313A1 (https=)
EP (1) EP3347368A4 (https=)
JP (1) JP2018526423A (https=)
CN (1) CN108350021A (https=)
AU (1) AU2016321254A1 (https=)
CA (1) CA2998134A1 (https=)
HK (1) HK1258588A1 (https=)
WO (1) WO2017044659A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119192266A (zh) 2011-10-14 2024-12-27 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2015010054A2 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2848823T3 (es) 2013-08-23 2021-08-12 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016123056A1 (en) 2015-01-26 2016-08-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA3003163A1 (en) 2015-10-29 2017-05-04 Senomyx, Inc. High intensity sweeteners
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US11060124B2 (en) 2017-05-03 2021-07-13 Firmenich Incorporated Methods for making high intensity sweeteners
CN108794556B (zh) * 2017-05-05 2021-01-29 清华大学 化合物及其在治疗白内障中的应用
RS67824B1 (sr) * 2017-06-08 2026-03-31 Eye Therapies Llc Oftalmološke kompozicije koje sadrže brimonidin i ketotifen za upotrebu u lečenju alergija
WO2019097434A1 (en) * 2017-11-17 2019-05-23 Mahmood Piraee Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
CN111386135B (zh) * 2017-11-22 2022-11-08 鲍希与洛姆伯股份有限公司 眼科粘弹性组合物
US20200276211A1 (en) * 2017-11-28 2020-09-03 Viewpoint Therapeutics, Inc. Compounds for treating near vision disorders
WO2019191200A1 (en) 2018-03-27 2019-10-03 American Genomics, Llc Method and formulation for producing anesthesia of internal aspect of eye wall by topical application
EP3813794A4 (en) * 2018-06-27 2022-07-13 Cellix Bio Private Limited COMPOSITIONS AND METHODS OF TREATMENT EYE DISEASES
CA3118467A1 (en) 2018-11-07 2020-05-14 Firmenich Incorporated Methods for making high intensity sweeteners
JP2022512931A (ja) 2018-11-07 2022-02-07 フィルメニッヒ インコーポレイテッド 高甘味度甘味料の製造方法
SG11202110423UA (en) * 2019-03-26 2021-10-28 Martin Uram Anesthetic composition and method of anesthetizing the eye
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
WO2021113411A1 (en) * 2019-12-02 2021-06-10 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations for vitamins, minerals and supplements
WO2021113410A1 (en) * 2019-12-02 2021-06-10 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations for vitamins, minerals and supplements
WO2022023822A1 (en) * 2020-07-30 2022-02-03 Indoco Remedies Limited A stable ophthalmic composition of posaconazole
WO2022031830A1 (en) * 2020-08-04 2022-02-10 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
US20220112208A1 (en) * 2020-10-08 2022-04-14 King Abdullah University Of Science And Technology Compounds with antiinflammatory activity and methods of use thereof
CN113583950A (zh) * 2021-08-06 2021-11-02 合肥滴碧云生物科技有限公司 一种制备干细胞活性因子的方法及其应用
CN115737654B (zh) * 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
CN119136683A (zh) * 2022-05-02 2024-12-13 祖姆森斯有限公司 耐降解含醛组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
FR2663850B1 (fr) * 1990-07-02 1994-01-14 Gird Galderma Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol.
US6821774B1 (en) * 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
US6281774B1 (en) * 1999-09-10 2001-08-28 Sumitomo Special Metals Co., Ltd. Corrosion-resistant permanent magnet and method for producing the same
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
US7906147B2 (en) * 2006-10-12 2011-03-15 Nanoprobes, Inc. Functional associative coatings for nanoparticles
WO2011075430A1 (en) * 2009-12-14 2011-06-23 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
KR20150036578A (ko) * 2012-07-17 2015-04-07 더 리젠츠 오브 더 유니버시티 오브 미시간 백내장의 치료를 위한 알파-크리스탈린 응집의 억제제
AU2014236582B2 (en) * 2013-03-14 2018-03-29 The University Of Massachusetts Methods of inhibiting cataracts and presbyopia
US10314917B2 (en) * 2013-03-15 2019-06-11 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles
JP2018522070A (ja) * 2015-07-27 2018-08-09 キャタコア・インコーポレイテッドＣａｔａｃｏｒｅ， Ｉｎｃ． 白内障の処置用組成物

Also Published As

Publication number Publication date
CN108350021A (zh) 2018-07-31
AU2016321254A1 (en) 2018-04-05
US20180250313A1 (en) 2018-09-06
EP3347368A1 (en) 2018-07-18
EP3347368A4 (en) 2019-01-23
WO2017044659A1 (en) 2017-03-16
HK1258588A1 (zh) 2019-11-15
JP2018526423A (ja) 2018-09-13

Similar Documents

Publication Publication Date Title
US20180250313A1 (en) Compounds and formulations for treating ophthalmic diseases
JP5292300B2 (ja) 例えばアルツハイマー病のようなアミロイドまたはアミロイド様タンパク質に関連する疾患の治療のためのｎ−（メチル）−１ｈ−ピラゾール−３−アミン誘導体、ｎ−（メチル）−ピリジン−２−アミン誘導体、およびｎ−（メチル）−トリゾール−２−アミン誘導体
JP2024059789A (ja) 老化細胞除去組成物及びその使用
US20250129054A1 (en) Prodrugs of 3,4-methylenedioxy-n-methcathinone and uses thereof
US20230257410A1 (en) Phenothiazine derivatives and uses thereof
TW202220664A (zh) 治療近視、預防近視及/或抑制近視進展之藥劑
AU2018312558B2 (en) Benzothiazole and related compounds
EP3192512B1 (en) Novel pharmaceutical composition for urinary incontinence prevention and/or treatment
US20260108494A1 (en) Therapeutic agent for non-motor symptoms associated with parkinson's disease
JP7011596B2 (ja) ピペリジニルノシセプチン受容体化合物
CA3157657A1 (en) 1,2,4-oxadiazole derivatives as liver x receptor agonists
WO2023137446A1 (en) Prodrugs of 3,4-methylenedioxy- n-ethyl-amphetamine (mdea) and uses thereof
JP2013510176A (ja) （１ｓ，２ｒ）−２−（アミノメチル）−ｎ，ｎ−ジエチル−１−フェニルシクロプロパンカルボキサミドの新規結晶形態
US20200276211A1 (en) Compounds for treating near vision disorders
US20240043396A1 (en) Methods of treating ocular fibrotic pathologies
CN114007693A (zh) 烟酰胺单核苷酸(nmn)及烟酰胺核苷(nr)的新用途
JP6744327B2 (ja) そう痒状態治療用化合物
US20260092037A1 (en) Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl) methyl)-3-chloro-5-fluorobenzamide and methods of use thereof
US20230322672A1 (en) Compounds and formulations for treating ophthalmic diseases
WO2005092339A1 (en) 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders
WO2026064443A1 (en) Methods for treating bestrophin-related diseases
JP2021500346A (ja) Ｒｅｔ９及びｖｅｇｆｒ２阻害剤
WO2021129843A1 (zh) 三唑并三嗪衍生物在治疗疾病中的用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220308